CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics

Tiwari, P. K., Ko, T.-H., Dubey, R., Chouhan, M., Tsai, L.-W., Singh, H. N., Chaubey, K. K., Dayal, D., Chiang, C.-W., & Kumar, S. (2023). CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics. Frontiers in Molecular Biosciences, 10. https://doi.org/10.3389/fmolb.2023.1214489
Authors:
Prashant Kumar Tiwari
Tin-Hsien Ko
Rajni Dubey
Mandeep Chouhan
Lung-Wen Tsai
Himanshu Narayan Singh
Kundan Kumar Chaubey
Deen Dayal
Chih-Wei Chiang
Sanjay Kumar
Affiliated Authors:
Himanshu Narayan Singh
Columbia Affiliation:
Author Keywords:
crispr/cas9
drug resistance and artificial intelligence
gene editing
immunotherapy
triple negative breast cancer
elink
Publication Type:
Article
Unique ID:
10.3389/fmolb.2023.1214489
PMID:
37469704
DOI:
10.3389/fmolb.2023.1214489
Journal:
Frontiers in Molecular Biosciences
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: